1.04
price down icon5.45%   -0.06
after-market Dopo l'orario di chiusura: 1.04
loading
Precedente Chiudi:
$1.10
Aprire:
$1.07
Volume 24 ore:
1.32M
Relative Volume:
0.55
Capitalizzazione di mercato:
$94.48M
Reddito:
-
Utile/perdita netta:
$-37.34M
Rapporto P/E:
-0.7647
EPS:
-1.36
Flusso di cassa netto:
$-36.91M
1 W Prestazione:
-6.31%
1M Prestazione:
-11.86%
6M Prestazione:
-17.46%
1 anno Prestazione:
-19.38%
Intervallo 1D:
Value
$1.02
$1.10
Intervallo di 1 settimana:
Value
$1.02
$1.125
Portata 52W:
Value
$0.772
$1.84

Sellas Life Sciences Group Inc Stock (SLS) Company Profile

Name
Nome
Sellas Life Sciences Group Inc
Name
Telefono
(646) 200-5278
Name
Indirizzo
7 TIMES SQUARE, NEW YORK, NY
Name
Dipendente
15
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
SLS's Discussions on Twitter

Confronta SLS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
SLS
Sellas Life Sciences Group Inc
1.04 94.48M 0 -37.34M -36.91M -1.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2021-07-21 Iniziato Cantor Fitzgerald Overweight
2018-11-01 Iniziato Oppenheimer Outperform
2018-04-02 Iniziato H.C. Wainwright Buy
2018-03-19 Aggiornamento Maxim Group Hold → Buy

Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie

pulisher
01:06 AM

Critical Review: SELLAS Life Sciences Group (NASDAQ:SLS) vs. CV Sciences (OTCMKTS:CVSI) - Defense World

01:06 AM
pulisher
Apr 02, 2025

Virtu Financial LLC Sells 38,086 Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) - Defense World

Apr 02, 2025
pulisher
Mar 31, 2025

Sellas Life Sciences: A Hold For Now With Huge, But Uncertain, Near-Term Catalyst (SLS) - Seeking Alpha

Mar 31, 2025
pulisher
Mar 28, 2025

Solaris Resources (CVE:SLS) Cut to Hold at Maxim Group - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Sellas Life Sciences Advances in Cancer Treatment Development - TipRanks

Mar 27, 2025
pulisher
Mar 26, 2025

Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail

Mar 26, 2025
pulisher
Mar 20, 2025

SELLAS LIFE SCIENCES GROUP I Earnings Results: $SLS Reports Quarterly Earnings - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

SELLAS Life Sciences Group, Inc. SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

SELLAS Life Sciences Group Inc. (SLS) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

SELLAS Life Sciences Group (SLS) to Release Earnings on Thursday - Defense World

Mar 20, 2025
pulisher
Mar 08, 2025

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Short Interest Update - Defense World

Mar 08, 2025
pulisher
Feb 27, 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 - The Malaysian Reserve

Feb 27, 2025
pulisher
Feb 26, 2025

SELLAS Life Sciences Group Inc (NASDAQ: SLS) Drops -2.59% In Early Trade; What Lies Ahead? - Stocks Register

Feb 26, 2025
pulisher
Feb 22, 2025

Biotech CEO predicts 'revolutionary' steps toward curing cancer on horizon thanks to AI - AOL

Feb 22, 2025
pulisher
Feb 21, 2025

Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment - Yahoo Finance

Feb 21, 2025
pulisher
Feb 21, 2025

SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial - MSN

Feb 21, 2025
pulisher
Feb 20, 2025

SELLAS reports promising DLBCL treatment trial results By Investing.com - Investing.com Nigeria

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL - GlobeNewswire

Feb 20, 2025
pulisher
Feb 20, 2025

3 AI Stocks Lawmakers Are Snapping Up Now - The Globe and Mail

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS Reports Positive Phase 2a Data For SLS009 With Zanubrutinib In Relapsed/Refractory DLBCL - Nasdaq

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS reports promising DLBCL treatment trial results - Investing.com

Feb 20, 2025
pulisher
Feb 20, 2025

SELLAS Life Sciences Reports Promising Phase 2a Data for SLS009 in Combination with Zanubrutinib in DLBCL Patients - Nasdaq

Feb 20, 2025
pulisher
Feb 12, 2025

SELLAS Life Sciences Group’s $25 Million Common Stock Offering - Global Legal Chronicle

Feb 12, 2025
pulisher
Feb 10, 2025

SELLAS Life Sciences Group Inc (NASDAQ:SLS) stock crossing the finish line today - US Post News

Feb 10, 2025
pulisher
Feb 10, 2025

Market Insight: SELLAS Life Sciences Group Inc (SLS)’s Notable Drop, Closing at 1.37 - The Dwinnex

Feb 10, 2025
pulisher
Feb 10, 2025

Wall Street analysts’ outlook for SELLAS Life Sciences Group Inc (SLS) - SETE News

Feb 10, 2025
pulisher
Feb 07, 2025

SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS) - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

SELLAS Life Sciences Group Inc (NASDAQ: SLS) Stock Has Gained 38.89% Over The Month – Is There Room For Growth? – Marketing Sentinel - Marketing Sentinel

Feb 06, 2025
pulisher
Feb 06, 2025

Orangekloud Technology Inc (NASDAQ: ORKT) Up 58.11% From 52-Week Low; YTD Falls -50.99% – Here’s What To Do Now – Marketing Sentinel - Marketing Sentinel

Feb 06, 2025
pulisher
Feb 06, 2025

Stock Traders Buy Large Volume of Call Options on SELLAS Life Sciences Group (NASDAQ:SLS) - MarketBeat

Feb 06, 2025
pulisher
Feb 05, 2025

Insider’s View: Deciphering SELLAS Life Sciences Group Inc (SLS)’s Financial Health Through Ratios - The Dwinnex

Feb 05, 2025
pulisher
Feb 04, 2025

Market Analysts see SELLAS Life Sciences Group Inc [SLS] gaining to $18. Time to buy? - The DBT News

Feb 04, 2025
pulisher
Feb 04, 2025

SELLAS Life Sciences Group Target of Unusually Large Options Trading (NASDAQ:SLS) - Defense World

Feb 04, 2025
pulisher
Feb 03, 2025

You Should Read This Analysis Before Investing in SELLAS Life Sciences Group Inc (NASDAQ:SLS) - US Post News

Feb 03, 2025
pulisher
Jan 31, 2025

Sellas Life Sciences Group Announces $25 Million Registered Direct Offering - Defense World

Jan 31, 2025
pulisher
Jan 30, 2025

Analysts Provide An Important Insights On SELLAS Life Sciences Group Inc (SLS) - Stocks Register

Jan 30, 2025
pulisher
Jan 29, 2025

SEC Form 424B5 filed by SELLAS Life Sciences Group Inc. - Quantisnow

Jan 29, 2025
pulisher
Jan 28, 2025

SELLAS secures $25 million in registered direct offering By Investing.com - Investing.com South Africa

Jan 28, 2025
pulisher
Jan 28, 2025

SELLAS secures $25 million in registered direct offering - MSN

Jan 28, 2025
pulisher
Jan 28, 2025

SELLAS Life Sciences Group Announces $25 Million Registered - GlobeNewswire

Jan 28, 2025
pulisher
Jan 28, 2025

Major Healthcare Investor Backs SELLAS with $25M DealHere's the Full Structure - StockTitan

Jan 28, 2025
pulisher
Jan 24, 2025

SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS) - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

SELLAS Life Sciences Announces Positive Phase 3 Trial Results - TipRanks

Jan 23, 2025
pulisher
Jan 23, 2025

SELLAS Life Sciences stock falls on GPS data (SLS:NASDAQ) - Seeking Alpha

Jan 23, 2025

Sellas Life Sciences Group Inc Azioni (SLS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Capitalizzazione:     |  Volume (24 ore):